AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01444534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
Study NCT01259713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
Study NCT01259713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
Study NCT01786356 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HOYA iMics Y-60H
Description: same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
Study NCT01786356 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: B&L MI60
Description: same-day bilateral cataract surgery with implantation of intraocular lens B\&L MI60 in one eye
Study NCT03502343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy
Description: All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -> 80%; Level 2: 80% -> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial.
Study NCT02587325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: nab-sirolimus is an mTOR inhibitor
Study NCT02236390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: 5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
Study NCT02236390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy - Cognitive
Description: 12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
Study NCT03576547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT03576547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Given PO
Study NCT03576547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03576547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT01658982 — intervention group
Intervention type: OTHER
Intervention: cardiopulmonary exercise testing
Description: 3 minute step test compared to 6 minute bicycle test
Study NCT04215120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desidustat Oral Tablet
Description: Desidustat tablet
Study NCT04215120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Epoetin Injection
Study NCT02706041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definitive Closure Laparotomy
Description: Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
Study NCT02706041 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Damage Control Laparotomy
Description: Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco flavored JUUL 1.7% ENDS
Description: Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco flavored JUUL 5% ENDS
Description: Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint flavored JUUL 1.7% ENDS
Description: Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint flavored JUUL 5% ENDS
Description: Treatment with Mint flavored JUUL 5% ENDS(10 puffs)
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit Medley flavored JUUL 1.7% ENDS
Description: Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit Medley flavored JUUL 5% ENDS
Description: Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crème brulee flavored JUUL 1.7% ENDS
Description: Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crème brulee flavored JUUL 5% ENDS
Description: Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 1.7% ENDS 10 puffs vs. ad lib puffs
Description: Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs
Study NCT03593239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5% ENDS 10 puffs vs. ad lib puffs
Description: Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
Study NCT02088294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Education (LS)
Description: See arm description
Study NCT02088294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LS + Stress Reduction Guided Imagery
Description: See Arm Description
Study NCT02088294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LS + Activity/Eating Guided Imagery
Description: See arm description
Study NCT00817778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Subjects will be treated with tolerable dose twice daily for another 24 days.
Study NCT00817778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be treated with tolerable dose twice daily for another 24 days.
Study NCT00504127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxcinod 375 mg bid
Description: Naproxcinod 375 mg bid
Study NCT00504127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxcinod 750 mg bid
Description: Naproxcinod 750 mg bid
Study NCT00504127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500 mg bid
Description: Naproxen 500 mg bid
Study NCT00504127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03663959 — intervention group
Intervention type: PROCEDURE
Intervention: vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier
Description: A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.
Study NCT03663959 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Pectocolpopexy procedure
Description: First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
Study NCT01715259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate: participants with end-stage renal disease
Description: abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
Study NCT01715259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate: matched control participants with normal renal function
Description: abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
Study NCT04650516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 20 minutes treatment in virtual reality
Study NCT04650516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital control
Description: 20 minutes digital control movie on tablet without virtual reality
Study NCT03341715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant (AFQ056)
Description: 2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
Study NCT03341715 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
Study NCT01027026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early discharge
Description: The patients are discharged the same day as coronary angiography.
Study NCT01027026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual. No intervention. (Control group)
Description: The patients are admitted and cared as usual in cardiology ward.
Study NCT01838863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Type AB plasma
Description: The plasma is thawed and administered to subjects in the experimental (plasma) arm.
Study NCT01838863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid fluid (standard of care for resuscitation)
Description: Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
Study NCT00179218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplementation
Description: oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
Study NCT00179218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: leg press exercise; every other day, 3 days per week, for 6 months
Study NCT01909817 — intervention group
Intervention type: PROCEDURE
Intervention: Routine coronary angiogram
Study NCT02832895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial doppler examination
Description: Assessment of frontal bone window for transcranial doppler
Study NCT06535282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: surgery
Description: Surgical treatment of conductive hearing loss with tinnitus
Study NCT03526185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
Study NCT03526185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: • Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
Study NCT03025659 — intervention group
Intervention type: OTHER
Intervention: Pyruvate levels
Description: An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
Study NCT00875537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin oral gel 0.025%
Description: Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
Study NCT00875537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin oral gel 0.01%
Description: Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
Study NCT00854386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liberal fluid administration
Description: patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
Study NCT00231166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCD122
Study NCT03796585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immunization Registry Training
Description: Education highlighting practical strategies to improve pharmacies' willingness to adopt the immunization registry and improve their ability to integrate the immunization registry into their pharmacy workflow.
Study NCT03796585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational flyer
Description: Informational flyer with ImmPRINT contact information
Study NCT03796585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational flyer
Description: Informational flyer with ImmPRINT contact information
Study NCT02255526 — intervention group
Intervention type: DEVICE
Intervention: BodyGuardian
Description: BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
Study NCT00832650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: 8 mg OD for 14 days
Study NCT00832650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: OD for 14 days
Study NCT00832650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Description: 10 mg OD for 14 days
Study NCT02814461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).
Study NCT02814461 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
Study NCT00958633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram will be prescribed in the dose range 10-30 mg daily.~* In patients randomized to the 8-week group, escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~* The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points.
Study NCT00958633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin XL
Description: Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~* In patients randomized to the 8-week group, bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~* The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points.
Study NCT02738918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nulojix (Belatacept)
Description: Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12
Study NCT00854386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restrictive fluid administration
Description: Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
Study NCT02365818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CG0070
Study NCT01211496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-speed power training
Description: High speed resistance training, 3 sessions per week for 12 weeks
Study NCT01211496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Slow-speed strength training
Description: Slow speed resistance training, 3 sessions per week for 12 weeks
Study NCT02354352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
Study NCT02354352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
Study NCT01838278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vojta Physiotherapy Method
Description: Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
Study NCT04557150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I.
Study NCT03927742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shade + app with messaging
Description: Shade wearable device and application with UV messaging activated
Study NCT00438932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Lanthanum carbonate 1000mg 3x/day
Study NCT00438932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Phosphorus Diet
Description: Low phosphorus diet will consist of 800 mg of phosphorus per day.
Study NCT00438932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unrestricted Phosphorus Diet
Description: Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
Study NCT00438932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lanthanum Carbonate placebo given three times a day with meals.
Study NCT03203005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA970A plus CV8102 and Cyclophosphamide
Description: Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms \[µg\] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months.